Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2025
Communicable Diseases Intelligence · 21.07.2026 · 50
DOI: 10.33321/cdi.2026.50.050 ↗Kurz gefasst
Fachartikel in der Zeitschrift Communicable Diseases Intelligence, online erschienen am 21.07.2026. Verfasst von Christiane Stehmann und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Florey Institute, The University of Melbourne, Victoria, 3010, Australia. Hauptthemen laut MEDLINE: Creutzfeldt-Jakob Syndrome. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Nationwide surveillance of Creutzfeldt-Jakob disease (CJD) and other human prion diseases is performed by the Australian National Creutzfeldt-Jakob Disease Registry (ANCJDR). National surveillance encompasses the period since 1 January 1970, with prospective surveillance occurring from 1 October 1993. Over this prospective surveillance period, considerable improvements have been developed in pre-mortem diagnostics in parallel with the delineation of new disease subtypes and heightened awareness of prion diseases in healthcare settings. Surveillance practices of the ANCJDR have evolved and adapted accordingly. This report summarises the activities of the ANCJDR during 2025. Since the ANCJDR began offering diagnostic cerebrospinal fluid (CSF) 14-3-3 protein testing in Australia in September 1997, the annual number of diagnostic test referrals has steadily increased. In 2025, there were 788 domestic CSF specimens referred for diagnostic testing; 92 persons with suspected human prion disease were formally added to the national register. As of 31 December 2025, more than half of the 84 initial case notifications for 2025 (44/84) remain classified as ‘incomplete’; 35 cases have been confirmed as ‘definite’ or ‘probable’ prion disease; five cases were excluded. In 2025, most suspected human-prion-disease-related deaths in Australia (56%) underwent neuropathological examination. No cases of variant or iatrogenic CJD were identified in Australia during 2025.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Florey Institute, The University of Melbourne, Victoria, 3010, Australia.
- Department of Medicine, The University of Melbourne, Victoria, 3010, Australia.
- The Florey Institute, The University of Melbourne, Victoria, 3010, Australia; The Alfred Hospital, Department of Anatomical Pathology, 55 Commercial Rd, Melbourne Vic 3004 Australia.
- The Florey Institute, The University of Melbourne, Victoria, 3010, Australia; Department of Medicine, The University of Melbourne, Victoria, 3010, Australia . s.collins@unimelb.edu.au.
Zitieren
APA
Stehmann, C., Senesi, M., Sarros, S., McGlade, A., Lewis, V., Klug, G., Holper, S., McLean, C., Masters, C., & Collins, S. (2026). Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2025. Communicable Diseases Intelligence, 50. https://doi.org/10.33321/cdi.2026.50.050
Vancouver
Stehmann C, Senesi M, Sarros S, McGlade A, Lewis V, Klug G, et al. Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2025. Communicable Diseases Intelligence. 2026;50. doi:10.33321/cdi.2026.50.050
BibTeX
@article{Stehmann2026,
author = {Stehmann, Christiane and Senesi, Matteo and Sarros, Shannon and McGlade, Amelia and Lewis, Victoria and Klug, Genevieve and Holper, Sarah and McLean, Catriona and Masters, Colin and Collins, Steven},
title = {Creutzfeldt-Jakob disease surveillance in Australia: update to 31 December 2025},
journal = {Communicable Diseases Intelligence},
year = {2026},
volume = {50},
doi = {10.33321/cdi.2026.50.050}
}
EUVIMED